

Appl. No. : 09/221,931
Filed : December 28, 1998

Claim 29. (New) The method according to claim 26, wherein the telomerase inhibitor further comprises pharmaceutically acceptable carrier or diluent.

Claim 30. (New) The method according to claim 26, wherein the telomerase inhibitor comprises the catechin in an amount of 90% to 95% by weight.

Claim 31. (New) The method according to claim 27, wherein the green tea extract contains epigallocatechin gallate in an amount of at least 10 wt%.

E1
cont
Claim 32. (New) The method according to claim 26, wherein an effective amount of the telomerase inhibitor is administered to a human subject having the cells exhibiting telomerase activity to contact the cells with the catechin.

Claim 33. (New) The method according to claim 26, wherein the telomerase inhibitor is topically administered.

Claim 34. (New) The method according to claim 33, wherein the telomerase inhibitor is topically administered by injection or plaster.

REMARKS

Claims 11 and 17-25 have been cancelled. New claims 26-34 are added. Claims 26-34 are now pending in this application. Support for the amendments is found in the existing claims and the specification as discussed below. Accordingly, the amendments do not constitute the addition of new matter. Applicant respectfully requests the entry of the amendments and reconsideration of the application in view of the amendments and the following remarks.

Support for claim amendments

Claim 1 is supported by Example 4 of the present specification and also claim 23. See line 9 of the Example at page 11 and also Figure 4. Claims 27-32 correspond to cancelled claims 17-22, respectively. Claims 33-34 correspond to cancelled claims 24 and 25, respectively. Claim 27 is supported by the present specification at page 5, lines 6-8. Claim 28 is supported by